INSM Upcoming Earnings (Q3 2023)
|Earnings Date:||Oct 25, 2023|
Current P/E* ratio: -4.99 | Price (Sep 29, 2023, EOD): $25.25
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 2 Quarters for INSM Premium
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutr... INSM Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.